Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 16/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 16/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 16/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.61 |
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650628 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C | |
| SCHEMBL27594116 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C | |
| SCHEMBL654518 | 0.94 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C | |
| SCHEMBL654517 | 0.94 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C | |
| SCHEMBL654519 | 0.94 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C | |
| SCHEMBL651058 | 0.89 | CHRNB2 (0.77) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL651056 | 0.89 | CHRNB2 (0.77) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL651057 | 0.89 | CHRNB2 (0.77) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL652711 | 0.86 | CHRNB2 (0.77) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C | |
| SCHEMBL652712 | 0.86 | CHRNB2 (0.77) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| CN-101357915-B | Diazabicyclic central nervous system active agents | ABBOTT LAB | 2011-07-06 | — | — | CN | disclosed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | disclosed |
| CN-101935322-A | Diazabicyclic central nervous system active agents | ABBOTT LAB | 2011-01-05 | — | — | CN | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| CN-101357915-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2009-02-04 | — | — | CN | disclosed |
| CN-100430398-C | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2008-11-05 | — | — | CN | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| CN-100355755-C | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2007-12-19 | — | — | CN | disclosed |
| CN-1765899-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2006-05-03 | — | — | CN | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| CN-1440410-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2003-09-03 | — | — | CN | disclosed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CHRNB2 10/4885CHRNB4 15/4885CHRNA3 14/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CHRNB2 10/4885CHRNB4 15/4885CHRNA3 14/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNB4 15/4885CHRNA3 14/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CHRNB2 10/4885CHRNB4 15/4885CHRNA3 14/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNB4 15/4885CHRNA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.